Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 4/20 | 0.62 |
| ▸ | GRIA4 | P48058 | 14/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13610004 | 0.84 | GRIA1 (0.75) | GRIA1GRIA4GRIA2GRIA3NPY5R | |
| SCHEMBL5107737 | 0.80 | GRIA1 (0.62) | GRIA1GRIA4GRIA2GRIA3 | |
| SCHEMBL7042049 | 0.77 | GRIA1 (1.00) | GRIA1GRIA4NPY5R | |
| SCHEMBL7109326 | 0.77 | GRIA1 (1.00) | GRIA1GRIA4NPY5R | |
| SCHEMBL8366386 | 0.77 | GRIA1 (0.65) | GRIA1GRIA4 | |
| SCHEMBL147252 | 0.77 | GRIA1 (0.65) | GRIA1GRIA4GRIA2GRIA3NPY5R | |
| SCHEMBL7039391 | 0.77 | GRIA1 (1.00) | GRIA1GRIA4NPY5R | |
| SCHEMBL12449172 | 0.76 | GRIA1 (0.71) | GRIA1GRIA4NPY5R | |
| SCHEMBL25435565 | 0.75 | GRIA1 (0.62) | GRIA1GRIA4GRIA2GRIA3NPY5R | |
| SCHEMBL4586639 | 0.75 | GRIA1 (0.62) | GRIA1GRIA4GRIA2GRIA3NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2021160127-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2021-08-19 | — | — | WO | disclosed |
| US-10654833-B2 | ASK1 isoindolin-1-one inhibitors and methods of use thereof | HEPATIKOS THERAPEUTICS, LLC (US) | 2020-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | GRIA1 1272/4885GRIA4 2525/4885GRIA2 2841/4885 |
| US-10654833-B2 | ASK1 isoindolin-1-one inhibitors and methods of use thereof | ATF1, MAP3K20, MAP3K1 | GRIA1 1911/4885GRIA4 3923/4885GRIA2 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.